FDA 483 - Biovectra, Inc. - April 19, 2024

BioVectra, Inc., an active pharmaceutical ingredient (API) contract manufacturer located in Charlottetown, Canada, underwent a Food and Drug Administration (FDA) inspection from April 15 to April 19, 2024. The resulting Form 483 report details two primary areas of concern regarding the facility's quality management and laboratory control systems. First, the inspection revealed that the company failed to follow its own written procedures for conducting regular quality reviews. Specifically, the Quality Control Unit did not complete Annual Product Reviews for all commercial products and intermediates, leaving several batch investigations unfinished. Notably, this was identified as a repeated deficiency from a previous inspection. Second, laboratory controls were found to be scientifically inadequate. Testing methods for identifying APIs through infrared spectroscopy did not meet United States Pharmacopeia (USP) standards, despite claims of compliance on product certificates. The FDA observed failures in qualifying reference standards, maintaining clear documentation, and ensuring that samples and standards were analyzed under consistent, traceable conditions. While the document does not represent a final compliance determination, BioVectra is expected to respond to these observations. The firm must provide a detailed plan of corrective actions to resolve these quality system failures and ensure future adherence to manufacturing standards.